Literature DB >> 7803543

Advances in the genetics and molecular biology of colorectal tumors.

G Thomas1.   

Abstract

Fascinating progress has been made in the past 2 years in our understanding of the genetic alterations associated with colorectal cancer predisposition and development. First, the genotype-phenotype relationship of the cancer susceptibility syndrome associated with familial adenomatous polyposis has been shown to depend on mutation type. Second, hereditary nonpolyposis colorectal cancer syndromes have been recognized as being frequently associated with a defect in the DNA mismatch-repair pathway. A gene on chromosome 2 called hMSH2, which demonstrates homology with the bacterial repair gene MutS, has been shown to be altered in some families with hereditary nonpolyposis colorectal cancer. A defect on chromosome 3 may act by impairing the same pathway. Genotyping of particular loci, termed microsatellite, provides an easy identification of tumors deficient in mismatch repair. Third, the mechanisms by which the inactivation of tumor-suppressor genes such as p53 and APC may contribute to the tumorigenic process have begun to be elucidated. These different discoveries will have important impacts in the prevention and management of colorectal carcinoma, one of the most frequent human cancers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7803543     DOI: 10.1097/00001622-199407000-00014

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  2 in total

1.  Prognostic markers for colorectal cancer: expression of P53 and BCL2.

Authors:  H Pereira; S Silva; R Julião; P Garcia; F Perpétua
Journal:  World J Surg       Date:  1997-02       Impact factor: 3.352

2.  p53 protein accumulation as a prognostic marker in sporadic colorectal cancer.

Authors:  Yuan-Tzu Lan; Shih-Ching Chang; Anna Fen-Yau Li; Tzu-Chen Lin; Wei-Shone Chen; Jeng-Kai Jiang; Shung-Haur Yang; Huann-Sheng Wang; Jen-Kou Lin
Journal:  Int J Colorectal Dis       Date:  2006-10-05       Impact factor: 2.796

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.